SCM
CRL icon

Sandler Capital Management’s Charles River Laboratories CRL Stock Holding History

Sandler Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-150,000
Closed -$10.6M – 143
2015
Q2 		$10.6M Buy
+150,000
New +$11.1M 0.94% 28

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sandler Capital Management's CRL Position: Q1 2025 in Review

Sandler Capital Management sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 57,718 shares — an estimated $10.7M sold.

Sandler Capital Management first reported a position in CRL in Q1 2015 and held it in 21 quarters. The position peaked at $65.6M in Q2 2021. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Sandler Capital Management reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Sandler Capital Management sold 57,718 Charles River Laboratories shares in Q1 2025, an estimated $10.7M.
  • Sandler Capital Management first reported a position in Charles River Laboratories in Q1 2015 and held it in 21 quarters.
  • Sandler Capital Management's Charles River Laboratories position peaked at $65.6M in Q2 2021.
  • 560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Sandler Capital Management's 13F filing for Q1 2025, filed 15 May 2025.